Background-Cardiovascular magnetic resonance is the gold-standard technique for the assessment of ventricular function.
S tudies in heart failure (HF) generally focus on the functional assessment of the left ventricle. Conversely, the right ventricle has received far less attention in the evaluation of HF patients. [1] [2] [3] [4] Much of this neglect stems from the fact that the right ventricle has complex structural and physiological properties that pose challenges for the assessment of its morphology and function. 2, 4, 5 However, adverse remodeling of the right ventricle is an important component of the HF syndrome. In particular, previous studies in HF cohorts of mixed etiology have suggested that right ventricular (RV) ejection fraction (RVEF), assessed by radionuclide or thermodilution techniques, may be a major determinant of exercise capacity and outcome. [6] [7] [8] [9] Consequently, there is growing interest regarding the clinical relevance of RV functional assessment in the HF population. 1, 3, 4 
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Dilated cardiomyopathy (DCM) is the second most common etiology of HF after coronary artery disease, 10 and remains the leading indication for cardiac transplantation. 11 Although the exact prevalence is poorly defined, RV systolic dysfunction (RVSD) has been reported in as many as 65% of DCM patients, 12 suggesting that DCM is frequently a biventricular disease. The potential prognostic impact of RV impairment in DCM has been highlighted by 2 small studies that suggested that RVSD is an independent predictor of survival. 13, 14 To date, the few studies evaluating RV systolic performance in DCM have used either thermodilution or contrast ventriculography to estimate RVEF. [12] [13] [14] Such techniques are invasive with the result that their clinical application is limited. In contrast, cardiovascular magnetic resonance (CMR) allows noninvasive measurement of RVEF with high accuracy and reproducibility. [15] [16] [17] [18] [19] Despite the fact that CMR is now firmly established as the gold standard for RV assessment, 4, 5, 20 CMR data regarding the prevalence and prognostic implications of RVSD in DCM are lacking. We therefore sought to prospectively evaluate the prevalence and prognostic significance of RVSD, as assessed by CMR, in a broad spectrum of DCM patients.
Methods

Patients
The study prospectively enrolled 250 consecutive patients with DCM (236 outpatients, 14 inpatients) who were referred for CMR by their treating cardiologist between November 2000 and March 2006. The diagnosis of DCM was made according to World Health Organization/ International Society and Federation of Cardiology criteria. 21 All patients had a left ventricular (LV) ejection fraction (LVEF) of <50% on transthoracic echocardiography of at least 6 months duration with no evidence of significant coronary artery disease (>50% diameter luminal stenosis in one or more epicardial vessels, history of myocardial infarction or coronary revascularization, or infarct pattern of late gadolinium enhancement). Before inclusion, the diagnosis of DCM was confirmed by CMR on the basis of increased LV end-diastolic volume indexed to body surface area and reduced LVEF, in comparison with published reference ranges normalized for age and sex. 22 Patients with a history of chronic lung disease, previous pulmonary embolism, or idiopathic pulmonary hypertension were excluded. Additional exclusion criteria were hypertensive heart disease, tachycardia-induced cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, infiltrative cardiomyopathy, hypertrophic cardiomyopathy, athletic heart, significant primary valvular disease, recent myocarditis (<6 months), or congenital heart disease. Significant coronary artery disease was excluded by angiography in 192 (77%) patients and negative stress imaging studies in 23 (9%) patients. The remaining 35 (14%) patients were <40 years of age, had no history of angina, and ≤1 risk factor for CAD. All patients provided written informed consent. The study was approved by the local institutional ethics committee.
Cardiovascular Magnetic Resonance
CMR was performed on a 1.5T scanner (Siemens Sonata or Avanto, Erlangen, Germany). A standardized protocol was used for all patients. After routine localizer images, cine images were acquired with a balanced steady-state free-precession pulse sequence and retrospective electrocardiographic gating during an end-expiratory breath hold. Cine imaging was first performed in horizontal and vertical long-axis planes, followed by the acquisition of a stack of contiguous short-axis cines at 10-mm intervals (7-mm slice thickness with 3-mm gap) from the atrioventricular ring to apex. Typical sequence parameters were as follows: repetition time, 3.2 ms; echo time, 1.6 ms; in-plane resolution of 2.1×1.3 mm; and flip angle, 60°. Late gadolinium enhancement (LGE) images were acquired 10 to 15 minutes after the intravenous administration of a gadolinium contrast agent (gadopentetate dimeglumine/gadobutrol; Schering, Germany; 0.1 mmol/kg) with the use of an inversion-recovery gradient echo sequence in identical long-axis and short-axis planes. Inversion times were adjusted to null normal myocardium with images repeated in 2 separate phase-encoding directions to exclude artifact.
CMR Analysis
Cine images were analyzed by using semiautomated software (CMR Tools, Cardiovascular Imaging Solutions, London) by a single experienced observer who was blinded to all clinical data. Ventricular volumes, ejection fraction, and LV mass were measured by standard techniques as previously described. 22, 23 In the case of the RV, this analysis involved 3 principal steps: (1) delineation of the RV endocardial border at end-diastole and end-systole; (2) semiautomated thresholding of the RV blood pool, with exclusion of papillary muscles and trabeculae, to determine RV end-diastolic volume and endsystolic volume; and (3) tracking of the tricuspid valve plane on the horizontal long-axis cine to correct for descent of the atrioventricular ring during systole. 23 Ventricular volumes and LV mass were indexed to body surface area. As per recent guidelines, RVSD was defined as RVEF ≤45%. 24 LGE images were assessed by a second independent blinded observer for the presence of RV or LV myocardial fibrosis. Fibrosis was only deemed to be present when the area of midwall LGE could be identified in both phase-encoding directions and in 2 orthogonal views.
To verify the reproducibility and reliability of RV functional assessment by CMR in our cohort, the intra-and interobserver variability were calculated for RVEF measurements in 25 randomly selected patients. For intraobserver variability, the RVEF was measured twice by the same observer with a minimum interval of 2 weeks between serial assessments. The interobserver variability was assessed by using the measurements obtained by a second independent observer blinded to all other analyses.
Follow-Up and End Points
All end points were adjudicated by the consensus of an independent committee blinded to the CMR findings. Mortality status was checked at 6-month intervals by the use of the National Strategic Tracing Service, a database for all National Health Service patients in the United Kingdom. In the event of death, the underlying cause was established from a combination of death certification, postmortem data where available, communication with the patients' primary care physicians and cardiologists, and review of medical records for patients who died in hospital.
Patients were contacted every 6 months by telephone interview and postal questionnaire to document the occurrence of nonfatal cardiac events over the follow-up period. This information was substantiated by communication every 6 months with the patients' primary care physician and cardiologist to facilitate the review of any new correspondence relating to outpatient clinic attendance or hospitalization. Following any hospital stay, the medical records were accessed to verify the cause of hospitalization and inpatient course.
The predefined primary end point was a composite of all-cause mortality or cardiac transplantation. Two additional secondary end points were prespecified: (1) cardiovascular mortality (sudden cardiac death, HF, stroke, or thromboembolic event) or cardiac transplantation; and (2) a HF composite of HF death, unplanned HF hospitalization, or cardiac transplantation. Mode of death was classified according to a modified Hinkle-Thaler system. 25 Sudden cardiac death was defined as unexpected death either within 1 hour of cardiac symptoms in the absence of progressive cardiac deterioration, during sleep, or within 24 hours of last being seen alive. HF death was defined as death associated with unstable, progressive deterioration of pump function despite active therapy. HF hospitalization was diagnosed in patients admitted to hospital with signs and symptoms of decompensated HF requiring treatment with intravenous HF medication (diuretics, vasodilators, or inotropic agents). Follow-up of patients who underwent cardiac transplantation was censored at the time of the procedure. Only the first event in each patient was included in the outcome analysis. categorical data and mean±standard deviation for continuous data. Differences between the 2 groups were assessed by the χ 2 or Fisher exact tests for categorical variables and the unpaired Student t test for continuous variables. Linear regression analysis was used to model the relationship between RVEF and LVEF. Intraobserver and interobserver variability was assessed by using the Bland-Altman method, 26 with results presented as mean differences and 95% limits of agreement.
The study population was divided into 4 subgroups based on RVEF value (>60%, 45%-60%, 30%-45%, <30%). Kaplan-Meier survival curves were constructed to estimate the cumulative event rate for each end point according to the presence or absence of RVSD and RVEF subgroup. Event times were measured from the date of CMR study to the index composite event. The log-rank test was used to compare the Kaplan-Meier survival curves. A univariable Cox proportional hazards model was used to analyze the relationship between baseline covariables and end points. Results are reported as hazard ratios (HRs) with 95% confidence intervals (CIs). To identify independent predictors of outcome, forward stepwise multivariable Cox regression analysis was performed. Candidate variables with a P value of <0.10 on univariable analysis were considered for entry and included in the multivariable model if they improved the likelihood ratio statistic by an amount that corresponded to a P value of <0.05. For each end point, 2 multivariable models were constructed based on the inclusion of either RVSD as a binary categorical variable or RVEF subgroup. Receiver operator characteristic curves were used to determine the optimal prognostic RVEF cutoff value (highest sum of sensitivity and specificity) for the primary end point of all-cause mortality or cardiac transplantation at 5 years of follow-up. The results for sensitivity, specificity, negative predictive value, and positive predictive value are given with their 95% CIs. The incremental prognostic value of RVSD for the prediction of the primary end point at 5 years, over and above other significant predictors in the multivariable model, was assessed by using net reclassification improvement. For each patient, the predicted 5-year risk of death/cardiac transplantation was determined on the basis of a Cox regression model with and without RVSD. Reclassification was examined by using 5-year risk thresholds of <5%, 5% to 10%, 10% to 20% and ≥20%. All analyses were conducted with Stata version 12 (StataCorp). A 2-tailed P value of <0.05 was considered statistically significant.
Results
Study Population
The study cohort comprised 250 patients whose baseline characteristics are summarized in Table 1 . The mean RVEF for the entire cohort was 48±13%. A total of 86 (34%) patients had RVSD. In comparison with patients without RVSD, patients with RVSD had a higher resting heart rate, lower systolic and diastolic blood pressures, more severe New York Heart Association (NYHA) functional class, and a lower prevalence of left bundle-branch block. There was no significant difference in age or sex between groups. At enrollment, patients with RVSD were more likely to receive treatment with β-blockers, angiotensin-converting enzyme inhibitors or angiotensin II antagonists, digoxin, loop diuretics, and aldosterone antagonists. RVSD was also associated with more severe biventricular adverse remodeling, with higher indexed ventricular volumes and lower LVEF in the RVSD+ group. On LGE-CMR, no patient was observed to have fibrous replacement of the RV free wall. However, LV midwall fibrosis was present in 28% of the cohort and was more prevalent in patients with RVSD. A positive correlation was observed between RVEF and LVEF measurements (r=0.58; P<0.001; Figure 1 ).
Intraobserver and Interobserver Variability
Analysis of both the intraobserver and interobserver variability showed high levels of agreement for the measurement of RVEF. The mean difference (95% limits of agreement) for the intraobserver study was 0.8% (−4.5, 6.0), whereas for interobserver study this was 0.7% (−6.6, 5.3).
Primary End Point
Patients were followed up for a median duration of 6.8 years (interquartile range, 5.9-8.1 years). Data were collected for a total of 1640 patient-years of follow-up. During follow-up, 52 patients died, and an additional 7 patients underwent cardiac transplantation for end-stage HF. The primary end point of allcause mortality or cardiac transplantation therefore occurred in 59 (24%) patients (Table 2 ). Figure 2A shows the event-free survival curves of the study population according to the presence or absence of RVSD as defined by an RVEF cutoff of 45%. Patients with RVSD had a significantly higher rate of all-cause mortality or cardiac transplantation (P<0.001). Among the 86 patients with RVSD, 42 (49%) patients reached the primary end point in comparison with only 17 (10%) of the 164 patients without RVSD (HR, 5.90; 95% CI, 3.35-10.37; P<0.001; Table 2 ). Additional significant univariable predictors of the primary end point are listed in Table 3 . After forward stepwise multivariable analysis, RVSD was the most significant independent predictor of all-cause mortality or cardiac transplantation (HR, 4.24; 95% CI, 2.31-7.78; P<0.001; Table 3 ). Other covariables that were found to be independently associated with transplant-free overall survival in the multivariable model were diastolic blood pressure (HR, 0.97; 95% CI, 0.95-1.00; P=0.026), NYHA class (HR, 1.70; 95% CI, 1.18-2.44; P=0.004), LV end-diastolic volume indexed to body surface area (HR per 10 mL/m 2 increment, 1.06; 95% CI, 1.01-1.12; P=0.018), and midwall fibrosis (HR, 3.27; 95% CI 1.88-5.67; P<0.001). RVSD remained a significant independent predictor of all-cause mortality alone with patients who underwent cardiac transplantation censored at the time of transplant (HR, 4.20; 95% CI, 2.24-7.90; P<0.001).
Kaplan-Meier survival analysis also showed a significant association between RVEF subgroup and the primary end point (P<0.001; Figure 3A) . In a multivariable Cox regression model, patients with an RVEF<30% (HR, 5.99; 95% CI, 1.33-26.95; P=0.020) or between 30% and 45% (HR, 7.75; 95% CI, 1.82-33.00; P=0.006) had a significantly higher risk of all-cause mortality or cardiac transplantation in comparison with those with an RVEF >60% (Table 3) . There was no difference in outcome between patients in the RVEF 45% to 60% or RVEF >60% subgroups (HR, 1.85; 95% CI, 0.41-8.29;
P=0.420).
Receiver operator characteristic analysis revealed that a cutoff of 45% was the optimal RVEF value for the prediction of all-cause mortality or cardiac transplantation at 5 years ( Figure 4) . At this cutoff, the sensitivity was 71% (95% CI, 56%-84%), specificity was 74% (95% CI, 67%-84%), positive predictive value was 37% (95% CI, 27%-48%), and negative predictive value was 92% (95% CI, 87%-96%) for the primary end point. The area under the receiver operator characteristic curve was 0.72 (95% CI, 0.65-0.80). 
Secondary End Points
Among the 52 deaths during the follow-up period, 43 (83%) were cardiovascular in etiology, including 21 sudden cardiac death, 20 HF deaths, and 2 deaths attributable to stroke or pulmonary embolism (Table 2) . Thirty-nine (16%) patients were hospitalized for the treatment of decompensated HF.
A total of 50 (20%) patients reached the secondary composite end point of cardiovascular mortality or cardiac transplantation ( Table 2 ). The presence of RVSD was associated with significantly worse outcome on Kaplan-Meier analysis (P<0.001; Figure 2B) Table 4 ). Kaplan-Meier estimates of transplant-free cardiovascular survival according to RVEF subgroup are shown in Figure 3B . There was a significant difference in the rate of cardiovascular death or transplantation between RVEF subgroups (P<0.001). Analysis between groups in the multivariable model revealed that this difference was primarily driven by the worse outcome observed in the RVEF <30% and RVEF 30% to 45% subgroups ( Table 4) .
The secondary HF composite end point of HF death, HF hospitalization, or cardiac transplantation occurred in 49 (20%) patients (Table 2) . Kaplan-Meier analysis revealed a significantly worse event-free survival rate among patients with RVSD (P<0.001; Figure 2C ). Table 4 ). Kaplan-Meier curves by RVEF subgroup demonstrated a stepwise increase in the incidence of the HF composite with decreasing RVEF (P<0.001; Figure 3C ). After multivariable analysis, the adjusted HRs for the HF composite in the RVEF <30%, 30% to 45%, and 45% to 60% subgroups, in comparison with the RVEF >60% subgroup, were 9.37 (95% CI, 1.18-74. 16 
Discussion
Risk stratification in DCM is important because of the associated morbidity and mortality attributable to HF and sudden cardiac death. 27, 28 Although current risk stratification is primarily guided by the degree of adverse LV remodeling, there is increasing appreciation of the potential impact of RVSD on outcome. 1, 3, 4 In this study, we investigated the prevalence and prognostic significance of RVSD, as identified by CMR, in a broad DCM cohort with a wide spectrum of phenotypic severity. Our results indicate that RVSD is present in approximately one-third of DCM patients and represents an independent and incremental marker of adverse prognosis. After adjustment for established prognosticators including LV parameters and NYHA functional class on multivariable analysis, patients with RVSD experienced a 4-fold increase in allcause mortality or cardiac transplantation. RVSD was also an independent predictor of transplant-free cardiovascular survival and HF outcomes. The assessment of RVSD improved risk stratification for transplant-free overall survival. These findings therefore suggest that assessment of RVEF, in addition to LV morphological and functional parameters, may further enhance the prognostic utility of CMR in DCM.
A number of imaging indices are available to evaluate RV systolic function. In addition to RVEF, other commonly used indices in the clinical arena include the tricuspid annular plane systolic excursion, tricuspid annular peak systolic velocity measured by tissue Doppler imaging, and RV fractional area change. Although tricuspid annular plane systolic excursion and tricuspid annular peak systolic velocity have been shown to correlate reasonably well with RVEF, [29] [30] [31] they are limited to the assessment of longitudinal systolic function, 32 dependent on RV loading conditions 4 and subject to confounding by significant LV systolic impairment 33, 34 and tricuspid regurgitation. 35 RV fractional area change is derived from a single 4-chamber view and may therefore be misleading in patients with regional contractile abnormalities. 5 In contrast, RVEF is more representative of global systolic performance. Consequently, although it is itself load-dependent, RVEF represents the most widely accepted and clinically validated index of RV contractility. 2 Accurate estimation of RVEF has historically been very difficult. Established techniques for RVEF assessment include transthoracic echocardiography, thermodilution, contrast or radionuclide ventriculography, and CMR. Because of its widespread availability, transthoracic echocardiography is typically the first line imaging technique for RV functional assessment. 4, 36 However, quantitative assessment of RVEF by transthoracic echocardiography depends on geometric modeling, which is problematic in the case of the RV owing to its asymmetrical crescentic shape, heavily trabeculated endocardial surface, and bellows-like contraction pattern. 2, 20 The substernal location of the RV poses further challenges for imaging by transthoracic echocardiography because of inadequate acoustic windows and suboptimal visualization of its anterior wall. 32, 37 Both thermodilution and contrast ventriculography are invasive, with the latter also limited by the complex RV geometry. The clinical application of these catheterization techniques for RV evaluation is therefore limited. Although noninvasive and independent of geometric modeling, radionuclide imaging requires exposure to ionizing radiation, has low spatial resolution, is susceptible to attenuation artifacts, and does not allow reliable delineation of the RV and right atrial cavities. 31 CMR offers several advantages with respect to RV assessment. The multiplanar imaging and 3-dimensional volume acquisition provided by CMR eliminate the need for geometric assumptions regarding RV shape. 16, 23 Balanced steady-state free-precession cine acquisitions yield high-spatial resolution images with excellent discrimination between blood and endocardium. 23 The high accuracy and reproducibility of CMR estimates of RV volumes and EF have been extensively validated, albeit predominantly in healthy individuals. [15] [16] [17] [18] [19] Assessment of the interobserver and intraobserver variability in RVEF measurement in our study population generated reproducibility measures comparable to those reported in healthy subjects. [16] [17] [18] [19] Our data therefore confirm the utility of CMR for reliable RVEF measurement in DCM, despite the adverse remodeling of the right ventricle that frequently accompanies this condition.
The normal range of RVEF varies depending on the methodology used for assessment. The accepted lower limit of radionuclide-derived RVEF is 40%. 38 Studies that have investigated the prognostic significance of RVEF measured by catheterization techniques most commonly used a cutoff value of 35% to define RVSD. 9, 12, 14 There is currently no international consensus regarding normal values for RVEF assessed by CMR. In a CMR study of 120 healthy subjects, Maceira et al 23 found that the lower limit of the 95% CI for RVEF varied from 48% to 59% depending on age and sex. In this study we defined RVSD according to an RVEF ≤45%, based on the value proposed by the recent modified Task Force Criteria for the identification of RVSD by CMR in arrhythmogenic right ventricular cardiomyopathy. 24 Receiver operator characteristic analysis demonstrated that an RVEF of 45% was also the optimal cutoff value for predicting the primary end point of all-cause mortality or cardiac transplantation at 5 years in our cohort. Subgroup analysis of patients with RVEF >45% revealed no significant difference in outcome between patients with RVEF 45% to 60% and those with RVEF >60% for any of the end points. An RVEF of 45% would therefore appear to represent a rational threshold for the CMR diagnosis of RVSD, both with respect to DCM phenotypic characterization and risk stratification. Although our study did not evaluate the underlying mechanisms of RVSD in DCM, the significant strong correlation observed between LVEF and RVEF is consistent with a pathophysiological link between left and right ventricular systolic function. LV systolic dysfunction may negatively impact RV contractility in DCM via multiple mechanisms, including increased afterload attributable to secondary pulmonary hypertension, RV involvement from the LV cardiomyopathic process, ventricular interdependence attributable to septal dysfunction, and myocardial ischemia secondary to reduced coronary perfusion pressure. 1 It has therefore been proposed that RVSD may signify a common final pathway in HF progression and provide a sensitive marker of future decompensation and poor prognosis accordingly. 1 Several previous reports have documented that impaired RVEF is an important prognostic factor in HF. [6] [7] [8] [9] However, this observation is based on the study of mixed HF cohorts of ischemic and nonischemic etiology, in which radionuclide ventriculography or thermodilution were used for RVEF measurement. The prognostic relevance of RVSD may vary according to HF etiology. In 2006, the National Heart, Lung and Blood Institute identified the study of RV function as a priority in cardiovascular research.
1 CMR represents the current gold-standard assessment for RVEF and yet, despite the recommendations of the National Heart, Lung and Blood Institute, there are no published CMR data regarding the prognostic implications of RVSD in either DCM or the general HF population. To the best of our knowledge, the present study is therefore the first to show that CMR assessment of RVEF predicts outcome in HF secondary to nonischemic DCM.
Our findings complement the few other studies to date that have previously examined the prevalence 12 and prognostic significance 13, 14 of RVSD in DCM. La Vecchia et al 12 found that RVSD was more common in patient with DCM versus those with ischemic HF, despite similar levels of LV impairment in the 2 groups. In their study, the prevalence of RVSD (defined by an RVEF <35%) in 92 DCM patients was as high as 65%, leading the authors to propose that RVSD may represent a marker for DCM. Although our data confirm that RVSD is relatively common in DCM, it was detected in only 34% of the study population. The lower prevalence observed in our cohort, despite the use of a higher RVEF threshold to define RVSD, may be attributed to differences in selection criteria and EF assessment methodology between the 2 studies. La Vecchia only enrolled DCM patients with at least moderate LV impairment at baseline (LVEF <45%) and used contrast ventriculography for both LVEF and RVEF measurement. In the present study, however, CMR was used to confirm DCM diagnosis at entry and to assess RVEF thereafter. The high fidelity of biventricular parameters assessed by CMR not only facilitates more accurate quantification of RVEF, but also allows confident diagnosis of DCM in patients with mild LV dilatation and dysfunction. 39 As a result, our cohort is composed of DCM patients with a wider spectrum of phenotypic severity, including those with mild or early disease.
Only 2 studies have previously evaluated the prognostic value of RVSD specifically in nonischemic DCM. 13, 14 Although both these studies also demonstrated that RVSD was associated with transplant-free overall survival, they were performed before the widespread incorporation of β-blockers into standard HF therapy, in small DCM cohorts (62-85 patients), in which RVEF was measured by invasive catheterization techniques. Only 1 study addressed whether RVSD was an independent predictor of outcome by using multivariable analysis. 13 However, this study did not include midwall fibrosis, another important prognosticator in DCM, [40] [41] [42] in the survival analysis. In contrast, we have investigated the prognostic impact of RVSD in a comparatively large cohort of DCM patients, who were accurately characterized by LGE-CMR and treated with contemporary HF pharmacological therapy, during a longer follow-up. On stepwise multivariable analysis, we have demonstrated that RVSD is not only an important predictor of transplant-free overall survival, but also predicts other hard end points, including cardiovascular mortality or cardiac transplantation, and HF death, HF hospitalization, or cardiac transplantation. Although cardiac transplantation is frequently used as a surrogate for cardiovascular death, analysis of overall survival excluding transplantation yielded similar results. The prognostic significance of RVSD is independent of established prognosticators, including measures of LV size and function and midwall fibrosis. Net reclassification improvement analysis further revealed that RVSD provided incremental predictive value for transplant-free survival in comparison with other independent risk predictors. Identification of RVSD by CMR therefore improves risk stratification in DCM and may help guide management decisions relating to patient selection and 
Study Limitations
The study cohort is selected in that it consists of DCM patients referred for CMR assessment by their treating cardiologists. Although this may potentially be subject to referral bias, we studied consecutive patients with a broad range of phenotypic severity. CMR measurement of RVEF from images acquired in the axial orientation may be more reproducible than the short-axis orientation used in this study. 16 We deliberately used the short-axis orientation because this is conventionally used in clinical practice since it allows simultaneous analysis of LV and RV parameters from a single data set. Our results additionally revealed good reproducibility with this method. In this study, RVEF was only measured at rest. The evaluation of RV contractile reserve may offer additive prognostic information. Owing to the limited number of events per candidate variable, there is a possibility of overfitting in our multivariate models, and further independent validation is needed. Renal function was not systematically recorded at the time of CMR assessment in all patients and is therefore not included in our analyses. Similarly, the absence of contemporaneous pulmonary arterial pressure measurements means that we were unable to elucidate the contribution of pulmonary arterial hypertension to the development of RVSD or outcome. However, accurate evaluation of pulmonary arterial pressure requires invasive right heart catheterization because the estimates derived from Doppler echocardiography are frequently inaccurate. 43 It was not deemed ethical to perform right heart catheterization in all study patients. Although CMR itself is unable to assess pulmonary arterial pressure, our study demonstrates that noninvasive assessment of RV function by CMR may additionally serve as an important prognostic marker.
Conclusions
RVSD is common in DCM with a prevalence of 34% in our cohort. Detection of RVSD by CMR represents a powerful independent predictor of transplant-free survival and adverse HF outcomes in DCM. Routine functional evaluation of the right ventricle is therefore warranted in the CMR examination of DCM patients for comprehensive phenotypic characterization and risk stratification. Further study is required to evaluate whether amelioration of RVSD, with treatments that target RV performance, may yet improve prognosis. 
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